If resmetirom hits the mark in the upcoming MAESTRO-NASH trial, Madrigal could leapfrog rival developers and bring the first drug to market for the treatment of patients with NASH and liver ...

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

Resmetirom significantly reduced liver stiffness in patients with compensated MASH cirrhosis, with a 6.7 kPa decrease over 2 years. The reduction in liver stiffness may lower the risk of liver ...